The inhibitor of vascular endothelial growth factor (VEGF) is one of the important target therapies used for treatment of metastatic cancers, including colorectal, breast, ovarian, and non-small cell lung cancers [3,4]. This evidence concerns the gene VEGFA and metastatic malignant neoplasm.